Search results for "CD4+"

showing 10 items of 566 documents

Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2021

BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 10 9 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.DESIGN: Multinational prospective cohort study.SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included…

MaleHIV AIDSHIV Infections0302 clinical medicineInterquartile rangeRisk FactorsNeoplasmsMedicine030212 general & internal medicineProspective StudiesProspective cohort study0303 health sciencesIncidenceAbsolute risk reductionDrugsGeneral MedicineMiddle AgedViral LoadAntiretroviral therapy3. Good healthAIDSCancer treatmentPrevention policy and public healthCohortInfectious diseasesCohort studiesFemaleViral loadAdultmedicine.medical_specialtyAnti-HIV AgentsHIV Infections/drug therapySocio-culturaleTime-to-Treatment03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingInternal medicineInternal MedicineHumansAdverse effect030306 microbiologybusiness.industryHIVCancermedicine.diseaseCD4 Lymphocyte CountCancer.Anti-HIV Agents/therapeutic use[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessNeoplasms/epidemiologyAnnals of Internal Medicine
researchProduct

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

2011

An investigation was undertaken to determine whether specific pol mutations hinder long-term immune recovery regardless of virological response. In total, 826 patients with >50 HIV RNA copies/ml, who underwent genotypic resistance testing between 1 January 2000 and 31 December 2003 after >3 years of antiretroviral treatment, and were followed up for >3 years after genotypic resistance testing, were analyzed retrospectively. The outcome of the study was the lack of immune recovery after >3 years of follow-up, defined as a slope by linear regression 50 copies/ml divided by the number of HIV RNA measurements during follow-up. Logistic regression was used for univariable and multivariable analy…

MaleHIV InfectionsDrug resistanceLogistic regressionResistance to nucleoside reverse transcriptase inhibitorCD4+ T-lymphocyteRetrospective StudieImmunopathologyAntiretroviral Therapy Highly ActiveResistance to non-nucleoside reverse transcriptase inhibitorgeneticsResistance to protease inhibitorHIV Infectionresistance to nucleoside reverse transcriptase inhibitorsViralSidaresistance to protease inhibitorsbiologyReverse-transcriptase inhibitorViral LoadGenes poldrug therapy/immunology/virologyReverse Transcriptase InhibitorInfectious DiseasesTreatment Outcomeresistance to non-nucleoside reverse transcriptase inhibitorsReverse Transcriptase InhibitorsFemaleViral loadmedicine.drugHumanpolAnti-HIV AgentsAntiretroviral TherapyViremiaInfectious DiseaseSettore MED/17 - MALATTIE INFETTIVEpharmacology/therapeutic useAcquired immunodeficiency syndrome (AIDS)VirologyDrug Resistance ViralmedicineHumansHighly ActiveRetrospective StudiesAnti-HIV Agents; pharmacology/therapeutic use Antiretroviral Therapy; Highly Active CD4 Lymphocyte Count Drug Resistance; Viral; genetics Female Genes; pol HIV Infections; drug therapy/immunology/virology HIV-1; drug effects/enzymology/genetics Humans Male Mutation Retrospective Studies Reverse Transcriptase Inhibitors; therapeutic use Treatment Outcome Viral Loaddrug resistanceAnti-HIV Agentbiology.organism_classificationmedicine.diseaseVirologyCD4 Lymphocyte CountGenesdrug effects/enzymology/geneticstherapeutic useMutationCD4+ T-lymphocytesHIV-1
researchProduct

Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1α and interleukin-12…

1995

Dendritic cells synthesize and express major histocompatibility complex (MHC) class II peptide-binding elements constitutively and, therefore, belong to the category of professional antigen-presenting cells. Unlike other cells that show constitutive class II expression, such as B cells and certain T cell clones, dendritic cells possess the unique capacity to activate naive T cells. Using dendritic cells generated in vitro by culture of mouse bone marrow in the presence of low doses of recombinant mouse granulocyte/macrophage colony-stimulating factor, we found that discrete maturation stages of these cells can be distinguished which were correlated with defined functional capabilities. The …

MaleImmunologyAntigen presentationBone Marrow CellsMicePhagocytosisBone MarrowAnimalsImmunology and AllergyCytotoxic T cellAntigen-presenting cellCells CulturedInterleukin 3Antigen PresentationMice Inbred C3HMHC class IICD40biologyFollicular dendritic cellsHistocompatibility Antigens Class IIDendritic CellsDendritic cellInterleukin-12Molecular biologyUp-RegulationCell biologybiology.proteinInterleukin-1European Journal of Immunology
researchProduct

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

2013

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.

MaleMultivariate analysisDatabases FactualDrug ResistanceHIV InfectionsDrug resistance0302 clinical medicineRetrospective StudieRisk FactorsEpidemiologyGenotypepol Gene Products Human Immunodeficiency ViruOdds RatioPrevalenceImmunology and AllergyHIV Infection030212 general & internal medicinepol Gene ProductsViralMultivariate Analysimedia_common0303 health sciencesDrug Resistance Prevalence HIV-1Middle AgedResistance mutation3. Good healthReverse Transcriptase InhibitorEuropeInfectious DiseasesReverse Transcriptase InhibitorsepidemiologyFemaleMultipleHuman Immunodeficiency VirusHumanDrugAdultmedicine.medical_specialtyGenotypeEvolutionmedia_common.quotation_subjectSexual Behaviorantiretroviral therapyInfectious DiseaseBiologySettore MED/17 - MALATTIE INFETTIVEEvolution Molecular03 medical and health sciencesDatabasesSDG 3 - Good Health and Well-beingDrug Resistance Multiple ViralmedicineHumansHIV Protease InhibitorFactualRetrospective Studies030306 microbiologyRisk FactorMolecularRetrospective cohort studyOdds ratioHIV Protease InhibitorsCD4 Lymphocyte Countantiretroviral therapy; drug resistance; epidemiology; genotyping; HIV-1; Adult; CD4 Lymphocyte Count; Databases Factual; Europe; Evolution Molecular; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sexual Behavior; pol Gene Products Human Immunodeficiency Virus; Drug Resistance Multiple Viral; Immunology and Allergy; Infectious Diseasesgenotypingpol Gene Products Human Immunodeficiency VirusImmunologyMultivariate AnalysisMutationHIV-1DemographyJournal of Infectious Diseases
researchProduct

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

2014

Splenic marginal zone lymphoma (SMZL) is a mature B-cell neoplasm characterized by rather indolent clinical course. However, nearly one third of patients experience a rapidly progressive disease with a dismal outcome. Despite the characterization of clone geneticsandthe recognition of deregulated immunologic stimulation in the pathogenesis of SMZL, little is known about microenvironment dynamics and their potential biological influence on disease outcome. Here we investigate the effect of stroma-intrinsic features on SMZL disease progression by focusing on the microenvironment of the bone marrow (BM), which represents an elective disease localization endorsing diagnostic and prognostic rele…

MalePathologyBiochemistryMiceTumor MicroenvironmentMast CellMedicineMast CellsInflammation MediatorAged 80 and overMice KnockoutB-LymphocytesMice Inbred BALB CMesenchymal Stromal CellB-LymphocyteCD40 AntigenCell DifferentiationHematologyMiddle AgedPrognosismedicine.anatomical_structureDisease ProgressionCytokinesFemaleInflammation MediatorsClone (B-cell biology)HumanAdultmedicine.medical_specialtyStromal cellPrognosiCD40 LigandImmunologyDisease-Free SurvivalAnimalsHumansSplenic marginal zone lymphomaCD40 AntigensCytokineB cellAgedCell ProliferationAnimalbusiness.industryMesenchymal stem cellMesenchymal Stem CellsLymphoma B-Cell Marginal ZoneCell BiologyGenes p53medicine.diseaseLymphomaSplenic marginal zone lymphoma bone marrow microenvironment CD40Mast cell sarcomaBone marrowbusinessBlood
researchProduct

Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in Ethiopia.

2012

Background Cutaneous leishmaniasis is a vector-borne disease that is in Ethiopia mainly caused by the parasite Leishmania aethiopica. This neglected tropical disease is common in rural areas and causes serious morbidity. Persistent nonhealing cutaneous leishmaniasis has been associated with poor T cell mediated responses; however, the underlying mechanisms are not well understood. Methodology/Principal Findings We have recently shown in an experimental model of cutaneous leishmaniasis that arginase-induced L-arginine metabolism suppresses antigen-specific T cell responses at the site of pathology, but not in the periphery. To test whether these results translate to human disease, we recruit…

MalePathologyCD3 ComplexBiopsyAntigens CD8Antigens CD3Antigens CD40302 clinical medicineINFECTIONSUPPRESSOR-CELLSAETHIOPICAChildImmune ResponseSOUTH-WESTERN ETHIOPIAIN-VIVOSkin0303 health sciencesbiologyPARASITOLOGYlcsh:Public aspects of medicine11 Medical And Health SciencesMiddle Aged3. Good healthArginaseInfectious Diseasesmedicine.anatomical_structureCD4 AntigensMedicineFemalemedicine.symptomLife Sciences & BiomedicineResearch ArticleNeglected Tropical DiseasesEXPRESSIONAdultmedicine.medical_specialtylcsh:Arctic medicine. Tropical medicineAdolescentlcsh:RC955-962CD8 AntigensT cellImmunology030231 tropical medicineLeishmaniasis CutaneousPeripheral blood mononuclear cellImmunomodulationLesionYoung Adult03 medical and health sciencesLeishmania aethiopicaCutaneous leishmaniasisTropical MedicineParasitic DiseasesL-ARGININE METABOLISMmedicineACTIVATED GRANULOCYTESHumansBiology030304 developmental biologyScience & TechnologyNITRIC-OXIDEArginasebusiness.industryPublic Health Environmental and Occupational HealthLeishmaniasislcsh:RA1-127006 Biological Sciencesbiology.organism_classificationmedicine.diseaseMICEImmunologyLeukocytes MononuclearEthiopiabusinessCD8PLoS Neglected Tropical Diseases
researchProduct

Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD

2009

BACKGROUND: Increased numbers of activated neutrophils have been reported in the bronchial mucosa of patients with stable chronic obstructive pulmonary disease (COPD), particularly in severe disease. OBJECTIVES: To investigate the expression of neutrophilic chemokines and adhesion molecules in bronchial biopsies from patients with stable COPD of different severity (GOLD stages I-IV) compared with age-matched control subjects, smokers with normal lung function and never smokers. METHODS: The expression of CCL5, CXCL1, 5, 6, 7 and 8, CXCR1, CXCR2, CD11b and CD44 was measured in the bronchial mucosa using immunohistochemistry, confocal immunofluorescence, real-time quantitative polymerase chai…

MalePulmonary and Respiratory MedicineChemokinePathologymedicine.medical_specialtyCOPD neutrophils bronchial mucosa CCL5 CXCL7BronchiRespiratory MucosaGranulocyteNeutrophil ActivationCCL5Pulmonary Disease Chronic ObstructiveneutrophilsSubmucosaCOPDHumansMedicineCXC chemokine receptorsChemokine CCL5AgedCOPDbronchial mucosaCCL5biologySettore BIO/16 - Anatomia UmanaCD11 Antigensbusiness.industryCD44Epithelial CellsMiddle Agedrespiratory systemmedicine.diseaseRespiratory Function Testsrespiratory tract diseasesCXCL1Hyaluronan Receptorsmedicine.anatomical_structureAcute DiseaseImmunologyCXCL7biology.proteinFemaleLeukocyte ElastasebusinessCOPD; neutrophils; bronchial mucosa; CCL5; CXCL7Chemokines CXCCOPD CCL5CXCL7NEUTROPHILThorax
researchProduct

Low bone mineral density in HIV-positive young Italians and migrants.

2020

Background Human immunodeficiency virus (HIV) infected individuals may have osteoporosis. We aimed to evaluate the bone mineral density (BMD) in naïve antiretroviral (ARV) treated HIV positive patients comparing native Italian group (ItG) to a Migrants group (MiG) upon arrival in Italy. Methods We conducted a cross-sectional study on 83 HIV patients less than 50 years old. We used the dual-energy X-ray absorptiometry (DXA) within six months from the HIV diagnosis. Participants were categorized as having low BMD if the femoral neck or total lumbar spine Z-score was– 2 or less. Results MiG showed low BMD more often than ItG (37.5% vs.13.6%), especially for the female gender (16.7% vs. 0.0%). …

MaleRNA virusesEuropean PeopleCritical Care and Emergency MedicineBone densityEpidemiologyOsteoporosisHIV InfectionsLogistic regressionPathology and Laboratory Medicine0302 clinical medicineAbsorptiometry PhotonImmunodeficiency VirusesBone DensityMedicine and Health SciencesEthnicities030212 general & internal medicineVitamin DConnective Tissue DiseasesMusculoskeletal SystemTrauma MedicineBone mineralTransients and MigrantsMultidisciplinaryQRvirus diseasesHuman immunodeficiency virus (HIV)HIV diagnosis and managementosteoporosis.Middle AgedItalian Peoplemedicine.anatomical_structureAnti-Retroviral AgentsItalyMedical MicrobiologyConnective TissueBone FractureViral PathogensVirusesMedicineInfectious diseasesFemalePathogensAnatomyTraumatic InjuryResearch ArticleAdultMedical conditionsmedicine.medical_specialtyScience030209 endocrinology & metabolismViral diseasesMicrobiology03 medical and health sciencesLumbarSex FactorsRheumatologyInternal medicineRetrovirusesmedicineVitamin D and neurologyHumansBoneMicrobial PathogensSkeletonFemoral neckbusiness.industryLentivirusOrganismsBiology and Life SciencesHIVBone fracturemedicine.diseaseDiagnostic medicineCD4 Lymphocyte CountCross-Sectional StudiesLogistic ModelsBiological TissueMedical Risk FactorsPeople and PlacesOsteoporosisPopulation GroupingsbusinessPloS one
researchProduct

CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke.

2009

Aim: Up-regulation of soluble CD40 ligand (sCD40L) and of monocyte chemoattractant protein-1 (MCP-1) has been found in diabetes and in patients with acute cerebral ischemia. We asked whether (i) the two molecules are similarly upregulated among non-lacunar and lacunar diabetic strokes and (ii) sCD40L and/or MCP-1 predict the risk of cardiovascular events in this setting.Methods: Ninety patients with type 2 diabetes mellitus presenting with an acute ischemic stroke (compared with 45 control subjects) were evaluated on admission and up to 36 months (median 24 months) after the event.Results: Diabetic patients with acute stroke had higher plasma CD40L and MCP-1 than controls (p<0.0001), wit…

MaleRiskCD40 ligand stroke diabetesmedicine.medical_specialtystrokeCD40L MCP-1Settore MED/09 - Medicina Internacerebral ischemia; chemokines; cytokines; diabetes mellitusCD40 LigandIschemiachemokinesDiseasecerebral ischemiaCohort StudiesDiabetes ComplicationsInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusMedicineCD40LHumanscardiovascular diseasesStrokeChemokine CCL2Ageddiabetesbusiness.industryProportional hazards modelBiochemistry (medical)Type 2 Diabetes MellitusMiddle Agedmedicine.diseasecytokinesSurgeryStrokeTreatment OutcomeQuartileGene Expression RegulationCardiologyRegression AnalysisFemaleCardiology and Cardiovascular MedicinebusinessCohort studyMCP-1
researchProduct

Soluble CD40L and Cardiovascular Risk in Asymptomatic Low-Grade Carotid Stenosis

2005

Background and Purpose— We investigated whether soluble CD40L (sCD40L) may predict the risk of cardiovascular (CV) events in patients with asymptomatic carotid plaques. Methods— Forty-two patients with asymptomatic low-grade carotid stenosis (ALCS) and 21 controls without any carotid stenosis were enrolled. All subjects had at least a major cardiovascular risk factor (CRF). Plasma levels of C-reactive protein (CRP), IL-6, and sCD40L were measured. Subjects were reviewed every 12 months (median follow-up, 8 years). Results— ALCS patients had higher ( P <0.0001) CRP, IL-6, and sCD40L than controls. Fourteen patients experienced a CV event. Cox regression analysis showed that only high sCD…

MaleRiskmedicine.medical_specialtySoluble CD40LCD40 LigandAsymptomaticatherosclerosiPredictive Value of TestsInternal medicineHumansrisk factorsMedicineRisk factorStrokeProportional Hazards ModelsAdvanced and Specialized NursingbiologyInterleukin-6business.industryProportional hazards modelVascular diseaseC-reactive proteinMiddle Agedmedicine.diseaseSurgeryStrokecarotid stenosiStenosisC-Reactive ProteinSolubilityinflammationPredictive value of testsbiology.proteinCardiologycarotid stenosisFemaleNeurology (clinical)atherosclerosismedicine.symptomatherosclerosis; carotid stenosis; inflammation; risk factorsCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesStroke
researchProduct